While cancer cure is still a vast and intriguing biologic conundrum, the conceptual barrier has been cracked.Chemotherapy alone as a cure has been focused on the qualitative difference in the unique gene recombination of chronic myelocytic leukemia.Although still early to claim cure, 89% of patients survive at 5 years, 1 without evident residual disease by the most sensitive methodology in a substantial fraction, which augurs well for a major cure rate.More tumors have joined the category of sub-curable, where chemotherapy together with surgery and/or radiation, and sometimes passive immunotherapy, has substantially increased cure rates for breast cancer and lymphomas.Palpable gains have been recognized for colon, lung, ovary, and squamous cell head and neck cancers.The existence of tumor stem cells has been invoked to account for chemotherapeutic failures.The chemotherapeutically curable tumors, choriocarcinoma, testis cancer, large cell lymphomas, Hodgkin's disease, and acute lymphocytic leukemia of children cast doubt on this invocation.The increased percentage of cures of acute myelocytic leukemia, acute lymphocytic leukemia in adults, chronic myelocytic leukemia, adjuvantly treated osteosarcoma and breast cancers, and several pediatric solid tumors, recognized by breaks in the survival curves, suggest that appropriate treatments can achieve tumor eradication.In the adjuvant treatment of breast